Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

This clinical trial is studying an experimental drug called tirapazamine to see how safe and effective it is when combined with a standard procedure called embolization. The study focuses on patients whose neuroendocrine tumors have spread primarily to the liver. Because tumors often have areas with very low oxygen, researchers are testing tirapazamine, a "hypoxia-activating" drug that is designed to become active and kill cancer cells specifically in those low-oxygen environments. During the procedure, a doctor will inject the drug directly into the artery feeding the liver tumor, followed by an embolization to block the blood flow. This blockage is intended to both trap the drug inside the tumor and create the low-oxygen conditions needed for the drug to work.

You may be eligible for this study if you have a well-differentiated neuroendocrine tumor that has spread to the liver and is continuing to grow. While you can have some cancer outside of the liver, the majority of your disease must be within the liver and take up no more than half of its total volume. You should have relatively good liver function and be healthy enough for a minor surgical procedure. Before enrolling, you should talk with your doctor about your previous treatments, such as surgery or systemic therapy, and discuss how this targeted liver treatment fits into your overall care plan. Participation involves specialized imaging like MRIs to track the treatment's effect, and you would only receive repeat treatments if the cancer shows signs of progressing.